Intra-Cellular Therapies Dividends and Buybacks
Dividend criteria checks 0/6
Intra-Cellular Therapies does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-6.2%
Buyback Yield
| Total Shareholder Yield | -6.2% |
| Future Dividend Yield | 0% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Revenues Tell The Story For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) As Its Stock Soars 26%
Nov 07
Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Strong Position To Grow Its Business
Sep 22Peaking Back In On Intra-Cellular Therapies
Sep 04Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Aug 10With Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) It Looks Like You'll Get What You Pay For
Jul 27Intra-Cellular Brightens MDD Outlook With Caplyta Success
Jun 19Intra-Cellular: More Upside Possible Even After Positive MDD Treatment Data
Apr 16Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) P/S Is On The Mark
Apr 09We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow
Mar 17Intra-Cellular Therapies Is On Fire
Mar 11Intra-Cellular Therapies: Buoyant Caplyta Sales And Upcoming MDD Data Support Short-Term 'Buy'
Feb 11Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) Price Is Out Of Tune With Revenues
Dec 24We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow
Nov 11Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Can Afford To Invest In Growth
Aug 07Here's Why We're Not At All Concerned With Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Situation
May 09After Leaping 31% Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Are Not Flying Under The Radar
Apr 17We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate
Jan 31Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Good Position To Deliver On Growth Plans
Oct 25Intra-Cellular Therapies: What Lies Ahead
Sep 20Intra-Cellular cut to Neutral at Goldman on trends for antipsychotic drug
Aug 22Intra-Cellular Therapies GAAP EPS of -$0.92 misses by $0.15, revenue of $55.6M beats by $6.98M
Aug 09We're Hopeful That Intra-Cellular Therapies (NASDAQ:ITCI) Will Use Its Cash Wisely
Jul 09Intra-Cellular Therapies: A Dramatic Story
Jun 18Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Are In A Position To Invest In Growth
Apr 03Intra-Cellular: Not Participating In A Bear Market
Mar 31Intra-Cellular; Long-Term To Own With A Few FDA Approvals And Ability To Expand
Mar 08Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if ITCI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ITCI's dividend payments have been increasing.
Dividend Yield vs Market
| Intra-Cellular Therapies Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (ITCI) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.2% |
| Industry Average (Pharmaceuticals) | 2.4% |
| Analyst forecast (ITCI) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate ITCI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ITCI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate ITCI's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ITCI has not reported any payouts.